Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena
News Jun 08, 2006
Better understanding of the ADME-Tox properties of potential drug candidates is an integral part of the pharmaceutical industry’s current strategy to reduce the attrition rate in bringing new drugs to the market.
Aureus’ ADME/DDI and hERG knowledge databases contain detailed data including metabolism, inhibition, drug-drug interactions and pharmacokinetics which can help assess the safety of a potential pharmaceutical candidate.
"Aureus Pharma’s knowledge databases on ADME and hERG provide Siena Biotech researchers access to important data to assess ADME properties early in the drug discovery process and complement our in-house knowledge-based drug design platform," commented Siena Biotech’s Dr. Graeme M. Robertson, Vice President Therapeutic Research.
"We are very pleased that Siena Biotech has chosen Aureus Pharma's solutions," said Dr. Andre Michel, CEO of Aureus Pharma.
"Having access to the data in our ADME & hERG knowledge databases allows scientists to save valuable research time by using this prior knowledge and improve prioritization in drug discovery process."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE